Verkazia

cyclosporine · CYCLOSPORINE 1 mg/mL · Emulsion · Ophthalmic; Topical · Santen Incorporated

NDC 65086-0001-05 · 1 POUCH in 1 CARTON / 5 VIAL, SINGLE-DOSE in 1 POUCH / .3 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

11 companies list this market (plus 1 repackager, which add no supply) — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

ⓘ How this was built

Data sources

FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
CMS NADAC — latest price vs the price in effect ~12 months earlier
FDA drug shortages and enforcement reports (openFDA)
FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model

Method

Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 82667-0014-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$15.84per unit

middle half $15.26–$16.01 · 169 plans · Apr 1, 2026

Est. net of rebatesⓘ

$9.50–$11.88

brand drug — est. 25–40% rebate off the price at left

Coverage & restrictions

3%of plans cover it

tier 5 · prior auth 32% · step therapy 0% · qty limit 20%

*No drug-level rebate is public — the estimate applies a 25–40% brand range derived from MedPAC's program-wide aggregates to this drug's gross price. Tracked here for 1 quarter since 2024.

NADAC price per unit

ⓘ How this was built

Data sources

CMS NADAC weekly files (data.medicaid.gov), December 2024 onward
CMS NADAC per-year archive files, 2013 – November 2024, averaged per month
CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the generic group (dashed line)

Method

One line, two regimes: before December 2024 each point is the average of that month's archived NADAC rows for this NDC; from December 2024 each point is a row from the weekly file, which CMS publishes only when the price changes, so the line holds flat until the next change and is extended to today when the last row is under 6 months old. Since the December 2024 file CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market. The dashed WAMP is the manufacturer-side average for the whole multiple-source group, not this NDC alone. To check a point: open the NADAC file for that date on data.medicaid.gov and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NDCs that have a NADAC price and a generic name.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for cyclosporine (other) in the next 90 days

OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is less than 1.5× that, which we treat as ordinary.

Backtested statistical model over the whole market, not this package alone. Model details →

ⓘ How this was built

Data sources

FDA NDC Directory labeler counts, CMS NADAC price trend, openFDA shortages and enforcement, FDA inspection classifications, Wayback archive of FDA's shortage list (labels)

Method

A logistic regression over molecule × dosage-form markets, trained on a monthly grid of historical dates since 2019 with labels equal to whether a new FDA shortage posting appeared within the following 90 days; eight features knowable on each date (labeler count, sole-source flag, NADAC year-over-year change, Class I/II recalls, injectable form, discontinuation filings, open shortage episodes, recent OAI inspection). The probability shown is the model's output for today's feature values; the reasons are the features pushing this market's probability up, listed only when the feature actually holds here. Held-out performance and coefficients are on the fragility page.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $2,017.51 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA214965
TE code: —
Approval date: Jun 23, 2021
Patents / exclusivity: 7 patents (7 unexpired), 1 exclusivity code (1 unexpired)

ⓘ How this was built

Data sources

FDA Orange Book data files — patent and exclusivity tables for application NDA214965, edition retrieved 2026-08-24

Method

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Type	Number / code	Expires
exclusivity	ODE-358	Jun 23, 2028
patent	9132071	Jun 2, 2029
patent	8298568	Nov 3, 2027
patent	7973081	Jan 27, 2026
patent	8524779	Jan 27, 2026
patent	9956289	Jan 27, 2026
patent	9220694	Jan 27, 2026
patent	11612658	Jan 27, 2026

Shortage history

ⓘ How this was built

Data sources

FDA drug shortages via openFDA (current file: Current, To Be Discontinued, and recently Resolved rows)
Internet Archive (Wayback) snapshots of FDA's shortage list since 2019, reconstructed into episodes
DrugDashboards Kaplan–Meier duration curves and conditional duration model

Method

Top rows are FDA's live listings whose package NDC is this product or another package of the same generic name and dosage form. openFDA drops resolved rows after about six months, so older episodes come from monthly Wayback snapshots of FDA's file, matched on the molecule with dosage-form words stripped (that matching can pull in other salts or forms of the same molecule — the presentation is shown so you can tell). 'Month N of a typical M' compares this episode's age with the Kaplan–Meier median for its form class (injectable, oral solid, other) over episodes since October 2019, open episodes censored; the resolution odds come from a model conditioned on the episode's age and reason. To check: FDA's drug shortage database, and web.archive.org for its history.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Not on FDA's current shortage list. Archived episodes below.

Archived episodes (FDA list history via Wayback, 2019+)

Planned discontinuation — AbbVie Inc., Gengraf, Oral Solution, 100 mg/ml (NDC 0074-7269-50) (listed as “Cyclosporine Oral Solution”)Dec 5, 2024 → last seen Aug 3, 2025
Planned discontinuation — Novartis Pharmaceuticals Corporation, Sandimmune, Solution, 100 mg/1 mL (NDC 0078-0110-22) (listed as “Cyclosporine Solution”)Aug 20, 2024 → last seen Aug 3, 2025
Planned discontinuation — Padagis US LLC, Injection, 250 mg/5 mL (50 mg/mL) in 5 mL Ampule (NDC 0574-0866-10) (listed as “Cyclosporine Injection”)Sep 29, 2023 → last seen Jul 18, 2024

Recalls (this NDC)

ⓘ How this was built

Data sources

FDA drug enforcement reports via openFDA

Method

Enforcement reports whose product NDC list includes this exact package NDC, newest first, with FDA's classification (I = reasonable probability of serious harm, II = temporary or reversible harm, III = unlikely to cause harm) and the recall's current status. Reports for other packages of the same drug are not shown here; 275 of the last year's Class I/II reports carry no NDC at all and cannot be matched. To check: search the recall number on openFDA or FDA's enforcement reports.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No enforcement reports list this package NDC.

Labelers of cyclosporine (Emulsion)

12 labelers active in the last 30 days, of which 1 is a repackager; 1not seen for 30+ days. Keyed on FDA's generic-name string — other salts or forms of the molecule are separate rosters.

ⓘ How this was built

Data sources

FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)

Method

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Labeler	Strengths	First seen	Last seen
Allergan, Inc.	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 3, 2026
A-S Medication Solutionsrepackager	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Apotex Corp	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Devatis Inc.	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Harrow Eye, LLC	CYCLOSPORINE 1 mg/mL	Jul 15, 2026	Sep 2, 2026
Kvk-Tech, Inc.	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Lupin Pharmaceuticals, Inc.	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Mylan Pharmaceuticals Inc.	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Santen Incorporated	CYCLOSPORINE 1 mg/mL	Jul 15, 2026	Sep 2, 2026
Saptalis Pharmaceuticals, LLC	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Teva Pharmaceuticals, Inc.	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Upsher-Smith Laboratories, LLC	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Sep 2, 2026
Amneal Pharmaceuticals NY LLC	CYCLOSPORINE .5 mg/mL	Jul 15, 2026	Jul 22, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 15, 2026.

Cite this page

DrugDashboards, "Verkazia — NDC 65086-0001-05," retrieved September 4, 2026, https://drugdashboards.com/drug/65086000105.

Free to cite with attribution — see how the data is put together.